Tiff Advisory Services LLC Sells 661,059 Shares of The Oncology Institute, Inc. $TOI

Tiff Advisory Services LLC lowered its stake in The Oncology Institute, Inc. (NASDAQ:TOI) by 77.2% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 195,569 shares of the company’s stock after selling 661,059 shares during the quarter. Oncology Institute comprises 0.1% of Tiff Advisory Services LLC’s portfolio, making the stock its 19th biggest holding. Tiff Advisory Services LLC’s holdings in Oncology Institute were worth $696,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. Pekin Hardy Strauss Inc. bought a new position in shares of Oncology Institute in the fourth quarter worth about $36,000. R Squared Ltd bought a new position in shares of Oncology Institute in the fourth quarter worth about $41,000. Prelude Capital Management LLC bought a new stake in Oncology Institute during the 3rd quarter valued at approximately $41,000. BNP Paribas Financial Markets raised its stake in Oncology Institute by 141.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 12,119 shares of the company’s stock valued at $42,000 after purchasing an additional 7,091 shares during the period. Finally, Sherbrooke Park Advisers LLC purchased a new position in Oncology Institute in the 3rd quarter worth approximately $51,000. Institutional investors own 36.86% of the company’s stock.

Oncology Institute Price Performance

Oncology Institute stock opened at $4.59 on Friday. The stock has a market cap of $453.68 million, a P/E ratio of -12.41 and a beta of 0.33. The Oncology Institute, Inc. has a 1 year low of $2.02 and a 1 year high of $4.88. The firm’s 50 day moving average price is $3.50 and its 200-day moving average price is $3.33.

Oncology Institute (NASDAQ:TOI) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.05. The company had revenue of $147.44 million for the quarter, compared to the consensus estimate of $142.10 million. As a group, equities analysts expect that The Oncology Institute, Inc. will post -0.2 EPS for the current year.

Insider Buying and Selling

In other news, major shareholder Jorey Chernett acquired 33,500 shares of Oncology Institute stock in a transaction on Wednesday, May 20th. The shares were acquired at an average price of $4.07 per share, with a total value of $136,345.00. Following the purchase, the insider directly owned 10,567,858 shares in the company, valued at $43,011,182.06. The trade was a 0.32% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Mohit Kaushal sold 38,433 shares of Oncology Institute stock in a transaction that occurred on Thursday, April 16th. The stock was sold at an average price of $3.50, for a total value of $134,515.50. Following the completion of the sale, the director directly owned 172,583 shares in the company, valued at approximately $604,040.50. The trade was a 18.21% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders acquired 637,485 shares of company stock worth $2,038,896. Corporate insiders own 8.50% of the company’s stock.

Analyst Ratings Changes

Several research analysts have weighed in on TOI shares. B. Riley Financial upped their price target on Oncology Institute from $6.00 to $8.00 and gave the stock a “buy” rating in a research note on Friday, March 13th. Needham & Company LLC reiterated a “buy” rating and set a $5.00 price objective on shares of Oncology Institute in a research report on Monday, March 9th. BTIG Research reiterated a “buy” rating and set a $7.00 price objective on shares of Oncology Institute in a research report on Monday, March 9th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Oncology Institute in a research report on Monday, April 20th. Four analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $7.00.

Oncology Institute Company Profile

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies.